About this medicine

The checked UK capsules cover several adult indications. Anafranil remains a cross-edition search name; a current UK branded formulation has not been verified here.

Clomipramine is a tricyclic medicine: that family name describes its chemical and pharmacological background, not a single diagnosis. The UK capsule licence is broader than the US OCD-only account, while the American paediatric age boundary and capsule strengths must not be imported.

What is this medicine used for?

Cataplexy is brief muscle weakness often triggered by emotion in narcolepsy. Clomipramine is an additional treatment for this symptom, not a licence for every sleep problem.

The checked adult licence covers depressive symptoms, particularly when sedation is required; obsessional and phobic states; and additional treatment of cataplexy associated with narcolepsy. Obsessions and compulsions can have a major effect on daily life, but medicine use should remain part of a properly assessed treatment plan rather than a response to ordinary habits.

Which warning signs need help?

Seek urgent help after excess doses, a seizure, collapse or new self-harm thoughts. Fever with confusion, agitation and twitching may signal serotonin syndrome. Severe palpitations or fainting also need immediate assessment.

MHRA’s October 2026 communication announced the rollout of a prominent boxed warning in UK antidepressant patient leaflets about self-harm and suicidal behaviour, alongside a patient safety card. This UK patient-information measure is not the US FDA Boxed Warning designation. Read the leaflet supplied with your medicine, seek prompt professional help for new or worsening mood or behaviour changes, and do not stop treatment suddenly without advice.

Tricyclic overdose can disrupt heart rhythm and cause seizures even when early symptoms seem limited. Seek immediate medical help after suspected overdose; do not wait for the next appointment. Fever or sore throat during treatment also warrants prompt advice because blood-cell problems, though uncommon, are possible.

How do I take it safely?

Adult product reference: depression starts at 10 mg daily and is increased gradually, often into a 30–150 mg daily range; severe cases may require up to 250 mg. Obsessional/phobic states and cataplexy have different schedules. The prescriber chooses the regimen; these figures are not self-titration instructions.

For obsessional or phobic states, the capsule label describes gradual movement from 25 mg daily towards 100–150 mg over about two weeks, with a lower initial amount in older or sensitive people. Cataplexy uses a distinct 10–75 mg daily range. These indication-specific examples require prescribing judgement, not automatic use of the highest depression dose.

A mention of a 75 mg sustained-release preparation in capsule prescribing text is not, by itself, verification that a specific current UK product is supplied. The verified panel here therefore retains the independently checked capsule strengths.

What side effects should I know about?

Dry mouth, constipation, nausea, sweating, tremor, sleepiness and sexual difficulties are recognised. Troublesome effects should be reviewed.

Persistent sexual effects, troublesome constipation or difficulty concentrating deserve discussion even when symptoms have improved. New confusion, mood elevation or unusual behaviour should not be dismissed as ordinary recovery; the team should assess whether treatment or another cause is involved.

Who needs extra care with this medicine?

Recent heart attack, rhythm/conduction disorders, severe liver disease, mania, narrow-angle glaucoma and urinary retention are important contraindications. Low potassium should be corrected before treatment.

Can it affect my other medicines?

MAO inhibitors must not be combined. The UK product specifies at least three weeks between clomipramine and irreversible MAO inhibitors in either direction. Other antidepressants, opioids and QT-prolonging medicines also need checking. Any switch must be professionally planned.

Other anticholinergic medicines can compound bowel, bladder and visual effects. Enzyme-inhibiting antidepressants can raise clomipramine exposure, while serotonergic combinations add a different risk. A safe review therefore considers both concentrations and overlapping actions; merely separating the time of day is not a solution.

What check-ups will I need?

Review mood, blood pressure and cardiac risk; blood count, liver tests or ECG monitoring may be required. Maintain regular dental care.

Monitor the outcome relevant to the indication: mood and function, obsessional distress or cataplexy frequency. Also review pulse, postural symptoms, bowel and bladder effects and dental health. Good symptom control does not remove the need to investigate fainting, infection symptoms or new confusion.

What about pregnancy, breastfeeding and age?

The checked leaflet is for adults only. Pregnancy and breastfeeding require individual professional assessment; older people usually need lower doses and closer supervision.

The checked SmPC does not recommend use during pregnancy and describes possible newborn effects after late exposure. It advises choosing between stopping breastfeeding and stopping treatment because medicine enters milk. That decision needs specialist discussion; neither abrupt withdrawal nor a blanket assurance of safety is appropriate.

What if I miss a dose or want to stop?

Abrupt withdrawal can cause symptoms. Agree a gradual reduction with the prescriber and never double a dose to compensate for forgetting.

Withdrawal and recurrence of the treated condition can overlap. Record the timing of nausea, sleep disturbance or new anxiety after a reduction so that the plan can be reviewed. A slower reduction may be needed; this article does not supply a universal taper.

How does it work?

Clomipramine slows reuptake, the return of serotonin and noradrenaline into nerve cells after these chemical messengers have been released. Proteins called transporters carry out this return process. Blocking some of their activity leaves more messenger available between cells, with clomipramine’s effect on serotonin reuptake particularly prominent.

This changes communication between nerve cells, but does not show that a person had a measurable serotonin deficiency. The strength of the transport effect in a laboratory cannot tell us how much someone’s symptoms will improve. Clinical benefit involves more than the immediate action at one protein.

How does it affect my body?

Dry mouth can increase dental problems. Drowsiness, blurred vision and difficulty passing urine reflect effects outside mood pathways.

Sedation may occur before the intended mood or obsessional benefit. Dryness, constipation, blurred vision and postural dizziness reflect effects in other body systems. Assess useful changes in symptoms and functioning separately from simply feeling sleepy.

How does my body process it?

The liver forms active desmethylclomipramine. Mean half-lives are about 21 hours for clomipramine and 36 hours for this metabolite.

First-pass liver metabolism changes some absorbed medicine into the active metabolite before it reaches the wider circulation. Concentrations vary substantially between people. The UK label's mean half-life estimates should not be replaced by the different dose-study figures in the American article.

How do treatment options differ?

Unlike a selective SSRI, clomipramine has broader receptor effects and significant cardiac and anticholinergic precautions. A shared indication does not make doses equivalent.

A closer look at the science

It also affects muscarinic, histamine and alpha-1 receptors. These additional actions help explain dryness, sedation and postural dizziness.

The active ingredient is supplied as the hydrochloride salt. Its tricyclic framework and chlorine-containing parent structure identify the molecule; they do not depict all the capsule ingredients or its active metabolite. Muscarinic and histamine effects help distinguish this broader-action medicine from a selective SSRI.

How was this medicine developed?

The 10 mg product’s recorded first authorisation was November 1990. This is a product milestone, not a discovery date.

A product's first authorisation is not the discovery date of the molecule. The UK adult indication wording and modern MHRA communication provide the relevant current context, while historical Anafranil recognition remains useful for finding the article.

The Oxford Health NHS formulary's indexed entry reports that sustained-release Anafranil SR preparations were discontinued in the UK. A reference to a 75 mg sustained-release tablet in another product's label therefore does not establish current supply. This record does not claim a current licensed UK 75 mg sustained-release product or infer foreign-product equivalence.

Sources and References

  1. Clomipramine 10 mg — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Clomipramine 25 mg — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Clomipramine 50 mg — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  4. Clomipramine 10, 25 and 50 mg — patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  5. Antidepressants: use and safety

    Scope: United Kingdom.

  6. Oxford Health NHS Foundation Trust formulary: clomipramine/Anafranil SR status

    Scope: England — Oxford Health local NHS formulary, not an exhaustive national authorisation record.

  7. Anafranil prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Clinical Pharmacology, Pharmacodynamics and Pharmacokinetics—Metabolism and Elimination; Warnings, Seizures. This does not establish UK product authorisation or prescribing..

  8. What Is a Neurotransmitter? — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How Neurotransmitters Work; Types of Neurotransmitters. This does not establish UK product authorisation or prescribing..

  9. Serotonin syndrome: MedlinePlus Medical Encyclopedia
  10. Monitoring a person during and after antidepressant switching – NHS SPS - Specialist Pharmacy Service – The first stop for professional medicines advice

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top